Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer
This study is intended to evaluate efficacy and safety of the combination of regorafenib and nivolumab as third-line or later therapy in patients with microsatellite stable (MSS) colorectal cancer (CRC).
Colorectal Cancer|Immunotherapy
DRUG: Regorafenib and PD-1 inhibitor
Objective Response Rate, Proportion of patients with reduction in tumor burden of a predefined amount, including complete remission and partial remission., Evaluation of tumor burden based on RECIST criteria through study completion, an average of 2 months|Progress Free Survival, Time from treatment beginning until disease progression, Evaluation of tumor burden based on RECIST criteria until first documented progress through study completion, an average of 2 months
Overall Survival, Time from treatment beginning until death from any cause, From date of treatment beginning until the date of death from any cause, through study completion, an average of 1 months|Adverse Effect, Incidence of Treatment-related adverse Events, Through study completion, an average of 1 months
This study is intended to evaluate efficacy and safety of the combination of regorafenib and nivolumab as third-line or later therapy in patients with microsatellite stable (MSS) colorectal cancer (CRC).